William Blair Reaffirms Outperform Rating for Neurogene (NASDAQ:NGNE)

Neurogene (NASDAQ:NGNE)‘s stock had its “outperform” rating reaffirmed by stock analysts at William Blair in a research report issued on Tuesday,RTT News reports. William Blair also issued estimates for Neurogene’s Q1 2026 earnings at ($1.18) EPS, Q2 2026 earnings at ($1.11) EPS, Q3 2026 earnings at ($1.14) EPS and Q4 2026 earnings at ($1.16) EPS.

Separately, HC Wainwright decreased their target price on shares of Neurogene from $55.00 to $50.00 and set a “buy” rating for the company in a research report on Tuesday. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $59.80.

Neurogene Stock Up 13.7 %

Shares of NASDAQ:NGNE opened at $16.14 on Tuesday. The firm has a fifty day moving average of $16.97 and a two-hundred day moving average of $29.06. Neurogene has a 12-month low of $13.47 and a 12-month high of $74.49. The firm has a market capitalization of $239.76 million, a P/E ratio of -3.78 and a beta of 1.01.

Neurogene (NASDAQ:NGNE) last released its quarterly earnings data on Monday, March 24th. The company reported ($0.99) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.04) by $0.05. The firm had revenue of $0.93 million for the quarter. Equities research analysts expect that Neurogene will post -4.27 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO Christine Mikail Cvijic sold 4,501 shares of the stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $16.94, for a total transaction of $76,246.94. Following the completion of the sale, the chief financial officer now owns 72,343 shares in the company, valued at $1,225,490.42. This represents a 5.86 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 9.92% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Casdin Capital LLC boosted its holdings in Neurogene by 146.9% in the 4th quarter. Casdin Capital LLC now owns 1,295,361 shares of the company’s stock valued at $29,612,000 after purchasing an additional 770,745 shares during the period. FMR LLC increased its stake in Neurogene by 912.4% during the third quarter. FMR LLC now owns 731,801 shares of the company’s stock valued at $30,706,000 after acquiring an additional 659,515 shares during the period. JPMorgan Chase & Co. lifted its position in shares of Neurogene by 10,395.3% in the 4th quarter. JPMorgan Chase & Co. now owns 481,001 shares of the company’s stock worth $10,996,000 after acquiring an additional 476,418 shares during the period. Samsara BioCapital LLC grew its holdings in shares of Neurogene by 35.4% during the 4th quarter. Samsara BioCapital LLC now owns 1,717,127 shares of the company’s stock worth $39,254,000 after purchasing an additional 449,337 shares in the last quarter. Finally, Deerfield Management Company L.P. Series C bought a new stake in shares of Neurogene during the fourth quarter valued at approximately $10,245,000. 52.37% of the stock is currently owned by institutional investors and hedge funds.

About Neurogene

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.